Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

Glimepiride [93479-97-1]

Research Use Only
CDX-G0208
Chemodex
CAS Number93479-97-1
Product group Chemicals
Estimated Purity>98%
Molecular Weight490.62
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Chemodex
  • Product Name
    Glimepiride [93479-97-1]
  • Delivery Days Customer
    10
  • CAS Number
    93479-97-1
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C24H34N4O5S
  • Molecular Weight
    490.62
  • Scientific Description
    Chemical. CAS: 93479-97-1. Formula: C24H34N4O5S. MW: 490.62. Glimepiride is a long-acting sulfonylurea antidiabetic agent inhibiting ATP-sensitive potassium (KATP) channels in pancreatic beta-cells, which leads to the release of insulin. In addition, Glimepiride increases the activity of intracellular insulin receptors. Studies conducted on adipocytes and skeletal muscle suggest that Glimepiride induces the PI3 kinase (PI3K) and Akt pathway, along with insulin receptor substrate-1/2 and endothelial nitric oxide synthase and stimulates glucose transporter 1 and 4 (GLUT1/4) expression. Glimepiride also increases osteoblast proliferation and differentiation, which is thought to be related to its ability to activate the PI3K and Akt pathway and exhibits neuroprotective benefit, decreasing expression and activity of BACE1 and amyloid-beta (Abeta) in neurons in a PPARgamma-dependent manner. - Glimepiride is a long-acting sulfonylurea antidiabetic agent inhibiting ATP-sensitive potassium (KATP) channels in pancreatic beta-cells, which leads to the release of insulin. In addition, Glimepiride increases the activity of intracellular insulin receptors. Studies conducted on adipocytes and skeletal muscle suggest that Glimepiride induces the PI3 kinase (PI3K) and Akt pathway, along with insulin receptor substrate-1/2 and endothelial nitric oxide synthase and stimulates glucose transporter 1 and 4 (GLUT1/4) expression. Glimepiride also increases osteoblast proliferation and differentiation, which is thought to be related to its ability to activate the PI3K and Akt pathway and exhibits neuroprotective benefit, decreasing expression and activity of BACE1 and amyloid-beta (Abeta) in neurons in a PPARgamma-dependent manner.
  • SMILES
    O=C(N1C(C(CC)=C(C)C1)=O)NCCC2=CC=C(S(NC(N[C@H]3CC[C@H](C)CC3)=O)(=O)=O)C=C2
  • Storage Instruction
    RT
  • UNSPSC
    12352200